troglitazone has been researched along with B-Cell Lymphoma in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Padilla, J | 1 |
| Kaur, K | 1 |
| Cao, HJ | 1 |
| Smith, TJ | 1 |
| Phipps, RP | 1 |
1 other study available for troglitazone and B-Cell Lymphoma
| Article | Year |
|---|---|
Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Lineage; Cells, Cultured; Chromans; Dinoprost; Hypoglycemic | 2000 |